PROVECTUS BIOPHARMACEUTICALS, INC. 4
4 · PROVECTUS BIOPHARMACEUTICALS, INC. · Filed Mar 31, 2016
Insider Transaction Report
Form 4
WACHTER ERIC PHD
DirectorVice President Pharmaceuticals
Transactions
- Exercise Out-of-Money
Common Stock
2016-03-29$1.00/sh+106,000$106,000→ 930,248 total(indirect: By 401(k)) - Exercise Out-of-Money
Common Stock Warrants (right to buy)
2016-03-29−306,947→ 359,719 totalExercise: $1.00From: 2012-11-16Exp: 2017-11-16→ Common Stock (306,947 underlying) - Exercise Out-of-Money
Common Stock
2016-03-29$1.00/sh+200,947$200,947→ 5,714,183 total - Exercise Out-of-Money
Common Stock Warrants (right to buy)
2016-03-29+306,947→ 306,947 totalExercise: $0.85From: 2016-03-29Exp: 2020-06-19→ Common Stock (306,947 underlying)
Holdings
- 4,867(indirect: By Trust)
Common Stock
Footnotes (1)
- [F1]On March 29, 2016, the reporting person exercised 306,947 warrants pursuant to the Issuer's warrant exchange offer, at a discounted exercise price of $0.50 per share. Under the terms of the warrant exchange offer, holders received, in addition to the common stock acquired upon exercise of their existing warrants, an equal number of new warrants to purchase the same number of shares of the Issuer's common stock at an exercise price of $0.85 per share that will expire June 19, 2020.